Popular Trials
Bisphosphonate
Zoledronic Acid for Parkinson's Disease
This trial is testing whether a single infusion of zoledronic acid can help prevent fractures in people with Parkinson's disease or parkinsonism. A total of 3500 participants will be enrolled in the United States.
Dietary Supplement
SCF Supplementation for Bone Health in Adolescents
This trial will study the effects of soluble corn fiber (SCF) supplementation on bone metabolism in growing adolescents compared to controls, by administering SCF or a placebo to adolescents aged 10-13 years, and assessing bone mass, bone related biomarkers, and the fecal microbiome at baseline and after 12 months.
Educational Interventions for Osteoporosis
This trial will focus on improving evidence-based osteoporosis diagnosis and treatment for women 50 and older who have suffered a fragility fracture. It will compare the current situation to an optimal one and propose interventions to improve care. The effectiveness of these interventions will be evaluated using a randomized control design.
Monoclonal Antibodies
Romosozumab for Osteoporosis in Multiple Myeloma
This trial is testing romosozumab, a medication that helps build and strengthen bones, in postmenopausal people with multiple myeloma. These patients often have weak bones due to osteoporosis and bone disease related to their condition. Romosozumab works by promoting new bone growth and preventing bone loss. Romosozumab is a recently approved monoclonal antibody that promotes bone formation and prevents bone resorption.
Popular Filters
Trials for Alopecia Patients
Cellular Regenerative Treatment
Cell + Plasma Therapy for Hair Loss
This trial is testing a new mixture of cells and plasma to see if it is safe and effective in treating hair loss. The mixture will be compared to a similar mixture and to a control group who will receive a standard treatment.
JAK Inhibitor
PF-06651600 for Alopecia Areata
This trial is testing a new drug to treat alopecia areata, which is an autoimmune disease that causes hair loss. The trial is open-label, which means all patients will receive the active drug. There is also a sub-study evaluating the immune response to vaccines in patients who have received the drug for at least 6 months.
Janus Kinase (JAK) Inhibitor
Baricitinib for Alopecia Areata
This trial is testing baricitinib to see if it is safe and effective for adults with severe hair loss due to alopecia areata. The drug works by calming the immune system to prevent it from attacking hair follicles. Baricitinib was approved by the FDA for treating severe alopecia areata.
JAK Inhibitor
CTP-543 for Alopecia Areata
This trial is testing CTP-543, a medication that may help people regrow hair by stopping the immune system from attacking hair follicles. It focuses on adults with chronic, moderate to severe alopecia areata. CTP-543 has shown promise in treating this condition.
Trials for Alopecia Areata Patients
Cellular Regenerative Treatment
Cell + Plasma Therapy for Hair Loss
This trial is testing a new mixture of cells and plasma to see if it is safe and effective in treating hair loss. The mixture will be compared to a similar mixture and to a control group who will receive a standard treatment.
JAK Inhibitor
PF-06651600 for Alopecia Areata
This trial is testing a new drug to treat alopecia areata, which is an autoimmune disease that causes hair loss. The trial is open-label, which means all patients will receive the active drug. There is also a sub-study evaluating the immune response to vaccines in patients who have received the drug for at least 6 months.
Janus Kinase (JAK) Inhibitor
Baricitinib for Alopecia Areata
This trial is testing baricitinib to see if it is safe and effective for adults with severe hair loss due to alopecia areata. The drug works by calming the immune system to prevent it from attacking hair follicles. Baricitinib was approved by the FDA for treating severe alopecia areata.
JAK Inhibitor
CTP-543 for Alopecia Areata
This trial is testing CTP-543, a medication that may help people regrow hair by stopping the immune system from attacking hair follicles. It focuses on adults with chronic, moderate to severe alopecia areata. CTP-543 has shown promise in treating this condition.
Phase 3 Trials
Radiation
IGIMRT Dosing Schedules for Cancer Spread to Bone/Spine
This trial is studying two ways of giving high-dose radiation for treatment of cancer that has spread to bone, the spine, soft tissue, or lymph nodes. One way is 27 Gy in three fractions (3 days) and the other is 24 Gy in one fraction (1 day).
JAK Inhibitor
PF-06651600 for Alopecia Areata
This trial is testing a new drug to treat alopecia areata, which is an autoimmune disease that causes hair loss. The trial is open-label, which means all patients will receive the active drug. There is also a sub-study evaluating the immune response to vaccines in patients who have received the drug for at least 6 months.
Janus Kinase (JAK) Inhibitor
Baricitinib for Alopecia Areata
This trial is testing baricitinib to see if it is safe and effective for adults with severe hair loss due to alopecia areata. The drug works by calming the immune system to prevent it from attacking hair follicles. Baricitinib was approved by the FDA for treating severe alopecia areata.
JAK Inhibitor
CTP-543 for Alopecia Areata
This trial is testing CTP-543, a medication that may help people regrow hair by stopping the immune system from attacking hair follicles. It focuses on adults with chronic, moderate to severe alopecia areata. CTP-543 has shown promise in treating this condition.
Trials With No Placebo
Device
AGN1 LOEP for Preventing Secondary Hip Fractures
This trial aims to test a new drug, AGN1, to see if it can prevent second hip fractures in women with osteoporosis who are already being treated for their first hip fracture. Around
Diagnostic Test
CT-Based Bone Assessment for Fracture Risk in COPD
This trial is testing a new tool to assess osteoporosis and bone loss in COPD patients, which may be more accurate than existing methods. The study will look at how different factors related to COPD impact bone structure and the risk of fractures.
Bone Property Testing for Fracture Risk
This trial is testing a new way to measure if someone is at risk for breaking a hip or radius. They think that women who have already fractured these bones have different bone properties than those who haven't, and that this new method can identify these differences.
View More Related Trials
Frequently Asked Questions
Introduction to osteoporosis
What are the top hospitals conducting osteoporosis research?
When it comes to advancing the treatment and understanding of osteoporosis, top hospitals across the United States are making significant contributions through their clinical trials. In West Orange, New jersey, the Kessler Institute for Rehabilitation is at the forefront with three active trials focused on this bone-weakening condition. Since conducting their first trial in 2006, they have been dedicated to finding innovative approaches to managing osteoporosis. Similarly, in the Bronx, New york, the James J. Peters VA Medical Center is actively involved in three ongoing trials and has recorded four all-time studies since initiating their first trial in 2015.
Moving westward to Aurora, Colorado's University of Colorado Anschutz Medical Campus joins this lineup with two active osteoporosis trials aiming to improve our understanding of this disease and develop novel treatments. Having commenced their first trial as recently as 2016 proves that they are committed to tackling one of today's pressing health concerns.
Meanwhile, UPMC Senior Communities located in Pittsburgh contributes significantly by conducting two ongoing clinical investigations into osteoporosis while having accomplished two prior trials since recording its pioneering investigation on such cases just five years ago back then from its very own establishment year itself i.e., also being conducted in 2016
Lastly but not leastly! The University of California Los Angeles (UCLA) rounds out this esteemed group with two currently running trials and a history of two completed studies dating back until thier earliest recorded involvement way back around2002 which adds substantial value towards expanding our knowledge base about how we can better manage or prevent Osteoporotic conditions.
These hospitals demonstrate an unwavering commitment not only towards improving patients' lives but also pushing boundaries within medical research communities; these tireless efforts will undoubtedly pave new paths toward improved prevention strategies and effective management techniques for individuals living with osteoporosis.
Which are the best cities for osteoporosis clinical trials?
When it comes to osteoporosis clinical trials, several cities have emerged as leaders in research and development. New york, with its 8 active trials, explores treatments such as Zoledronic acid (ZA), Romosozumab, and Vital signs. Aurora, Colorado follows closely behind with 7 ongoing studies focused on interventions like Exercise, Zoledronic acid (ZA), and Calcium Infusion. Additionally, Chicago in Illinois boasts 7 active trials examining treatments such as Zoledronic acid (ZA), Romosozumab, and Surgical Intervention. Lastly, Boston in Massachusetts offers 7 active trials investigating options like Zoledronic acid (ZA), Reference Point Indentation, and Romosozumab/denosumab combination therapy. Pittsburgh in Pennsylvania also contributes to the advancement of osteoporosis care with its 5 ongoing trials centered around treatments like Romosozumab and Zoledronic Acid. These cities serve as hubs for cutting-edge clinical research that aims to improve outcomes for individuals affected by osteoporosis.
Which are the top treatments for osteoporosis being explored in clinical trials?
Osteoporosis research is advancing rapidly, with several promising treatments taking center stage in clinical trials. Leading the pack is romosozumab, currently being explored in four active trials for osteoporosis. Since its introduction in 2009, it has been involved in a total of 16 clinical trials dedicated to this condition. Another notable contender is denosumab, which has two ongoing trials and an impressive history of 47 all-time osteoporosis studies since its first listing in 2003. Finally, we have donepezil making waves as well with one active trial and marking its debut on the scene in 2023 specifically for osteoporosis exploration. These developments offer hope for improved treatment options to combat this common bone disorder.
What are the most recent clinical trials for osteoporosis?
Exciting advancements in the field of osteoporosis treatment are underway, as recent clinical trials offer new possibilities for patients. One notable trial explores the potential benefits of donepezil, a medication traditionally used to treat Alzheimer's disease, in tackling osteoporosis. Another study focuses on romosozumab, which has shown promise as a therapy for this condition during its Phase 1 investigation. Additionally, zoledronic acid is being examined in a Phase 4 trial to assess its effectiveness and safety profile further. These significant research endeavors aim to enhance our understanding and management of osteoporosis while providing hope for improved outcomes moving forward.
What osteoporosis clinical trials were recently completed?
In the realm of osteoporosis research, several recent clinical trials have made strides in advancing our understanding and treatment options. Teva Pharmaceuticals USA completed a trial for TVB-009 in March 2021, while Roswell Park Cancer Institute wrapped up their investigation into Denosumab in December 2019. Additionally, Sandoz concluded its GP2411 study in July 2019. These trials demonstrate ongoing efforts to combat osteoporosis and provide hope for improved therapies that can alleviate the burden this condition places on individuals' bone health.